EUCTR2007-002448-10-SK进行中（未招募）1 期
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic control
未提供0 个研究点目标入组 450 人开始时间: 2008年5月7日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed and dated informed consent
- •Type 2 diabetes mellitus, treated with a maximum of 1 antidiabetic drug.
- •HbA1c >=6.5 and =<9% at start of wash-out of current medication and >=7%, =<10% after wash-out
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Myocardial infarction, stoke or TIA wihtin 6 months prior to consent
- •Impaired hepatic function
- •Treatment with glitazones, GLP-1 analogues or insulin within 3 months prior to consent
- •Treatment with more than 1 antidiabetic drug within 10 weeks prior to consent
研究者
相似试验
进行中（未招募）
1 期
A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF).MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary FibrosisEUCTR2019-004167-45-FIBoehringer Ingelheim Finland Ky150
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylureaEUCTR2007-002450-28-BESCS Boehringer Ingelheim Comm.V800
进行中（未招募）
不适用
Tiotropium-bromide in cystic fibrosicMedDRA version: 14.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2010-019802-17-CZBoehringer Ingelheim360
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 years of age, with type 2 diabetes and insufficient glycaemic control despite treatment with diet and exercise alonePatients with type 2 diabetes.MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-017004-91-FRBoehringer Ingelheim France83
进行中（未招募）
1 期
Effic. PK + safety in paed. patientsPatients with type 2 diabetes.MedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-017004-91-ITBOEHRINGER ING.255